ibandronic acid has been researched along with osteoprotegerin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Biskobing, DM; Downs, R; Novy, AM | 1 |
| Nguyen, TM; Price, PA; Than, TN; Williamson, MK | 1 |
| Geusens, P; Reid, D | 1 |
| Blair, JM; Brennan, K; Dunstan, CR; Modzelewski, JR; Seibel, MJ; Zheng, Y; Zhou, H | 1 |
| Masuda, H; Tanaka, S | 1 |
| Al-Nawas, B; Koch, FP; Merkel, C; Smeets, R; Walter, C; Ziebart, T | 1 |
| Brzeziańska, E; Cegłowska, A; Liberski, PP; Rieske, P; Sewerynek, E; Stêpień-Kłos, W; Stuss, M | 1 |
| Criscitiello, C; Curigliano, G; De Laurentiis, M; De Placido, S; Esposito, A; Gelao, L; Goldhirsch, A; Santangelo, M; Viale, G | 1 |
| Jędrzejczyk, S; Król, I; Sewerynek, E; Stępień-Kłos, W; Stuss, M | 1 |
| Li, N; Liao, Y; Sun, G; Wu, Q; Xie, H; Zeng, Y; Zhou, G; Zhou, J | 1 |
| Abualhamael, SA; Baig, M; Malik, AA; Shahzad, M; Tariq, S | 1 |
4 review(s) available for ibandronic acid and osteoprotegerin
| Article | Year |
|---|---|
Novel therapeutic options for osteoporosis.
Topics: Animals; Controlled Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Evidence-Based Medicine; Fractures, Spontaneous; Glycoproteins; Humans; Ibandronic Acid; Imidazoles; Norpregnenes; Osteoporosis; Osteoprotegerin; Piperidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Selective Estrogen Receptor Modulators; Thiophenes; Zoledronic Acid | 2002 |
Newer drug treatments: their effects on fracture prevention.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Denosumab; Diphosphonates; Fractures, Bone; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Organometallic Compounds; Osteoporosis; Osteoprotegerin; Parathyroid Hormone; RANK Ligand; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thiophenes; Zoledronic Acid | 2005 |
[Drugs under development for osteoporosis ].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cathepsin K; Cathepsins; Denosumab; Diphosphonates; Drug Design; Humans; Ibandronic Acid; Imidazoles; Organometallic Compounds; Osteoporosis; Osteoprotegerin; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes | 2009 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bone Remodeling; Bone Resorption; Clodronic Acid; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Immune System; Osteoclasts; Osteoprotegerin; Pamidronate; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Treatment Outcome; Zoledronic Acid | 2015 |
1 trial(s) available for ibandronic acid and osteoprotegerin
| Article | Year |
|---|---|
Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Cholecalciferol; Combined Modality Therapy; Dietary Supplements; Diphosphonates; Female; Gene Expression Regulation; Humans; Ibandronic Acid; Leukocytes, Mononuclear; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; RNA, Messenger; Thiophenes | 2013 |
6 other study(ies) available for ibandronic acid and osteoprotegerin
| Article | Year |
|---|---|
Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat.
Topics: alpha-Fetoproteins; Animals; Aorta, Abdominal; Aortic Diseases; Bone Resorption; Calcinosis; Diphosphonates; Glycoproteins; Ibandronic Acid; Male; Minerals; Osteoprotegerin; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Vitamin D | 2004 |
Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Therapy, Combination; Female; Ibandronic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoprotegerin; Tibia; Xenograft Model Antitumor Assays | 2007 |
Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro.
Topics: Bone Density Conservation Agents; Cell Culture Techniques; Cell Line; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Ibandronic Acid; Imidazoles; Osteoblasts; Osteoprotegerin; RANK Ligand; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Zoledronic Acid | 2012 |
Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Remodeling; Diphosphonates; Drug Therapy, Combination; Female; Humans; Ibandronic Acid; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Thiophenes | 2016 |
Effects of combined treatment with ibandronate and pulsed electromagnetic field on ovariectomy-induced osteoporosis in rats.
Topics: Animals; Biomechanical Phenomena; Bone Density; Combined Modality Therapy; Diphosphonates; Electromagnetic Fields; Female; Femur; Gene Expression Regulation; Ibandronic Acid; Magnetic Field Therapy; Osteoporosis; Osteoprotegerin; Ovariectomy; RANK Ligand; Rats; RNA, Messenger; Spine; Tartrate-Resistant Acid Phosphatase; X-Ray Microtomography | 2017 |
Osteoprotegerin genetic polymorphisms and their influence on therapeutic response to ibandronate in postmenopausal osteoporotic females.
Topics: Bone Diseases, Metabolic; Case-Control Studies; Female; Humans; Ibandronic Acid; Osteoprotegerin; Polymorphism, Single Nucleotide; Postmenopause | 2023 |